Universal API Implementation Guide
1.1.20 - ci-build
Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
Copay Questionnaire: OCREVUS Indication for pediatric-ms is available in production and all test environments as of 6/18/2026
Copay Questionnaire: New linkId form-of-Ocrevus-pediatric for OCREVUS is available in production and all test environments as of 6/18/2026
| Type | Release to Production |
Available in QA (test) environment? | Product(s) impacted | linkId impacted (if applicable) | OLD | New | Comment |
|---|---|---|---|---|---|---|---|
| Add | 6/18/2026 | Yes | Ocrevus | linkId: ocrevus-fda-approved-indications | - | valueCoding.code: pediatric-ms valueCoding.display: Relapsing remitting MS, in pediatric patients 10 years of age and older who weigh 55 pounds (25 kg) or more |
New pediatric-ms Indication |
| Add | 6/18/2026 | Yes | Ocrevus | linkId: ocrevus-form-of-ocrevus-pediatric text: "Which form of OCREVUS is the patient taking?" |
- | Question is ONLY required when Indication is "Relapsing remitting MS, in pediatric patients 10 years of age and older who weigh 55 pounds (25 kg) or more" |
Answer option: Intravenous infusion (IV) for OCREVUS |
| Update | 6/18/2026 | Yes | Ocrevus Ocrevus Zunovo |
linkId: ocrevus-form-of-ocrevus text: "Which form of OCREVUS is the patient taking?" |
Always required | Question is ONLY required when Indication is "Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease or primary progressive forms of MS, in adults" |
Answer options: - Intravenous infusion (IV) for OCREVUS -Subcutaneous (SC) injection for OCREVUS ZUNOVO |